MANUSCRIPT TITLE:
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0
Draft Manuscript Summary
The Society for Immunotherapy of Cancer (SITC) Acute Leukemia (AL) Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0,” an update to the society’s 2020 CPG for this disease setting.
The new AL manuscript is part of the broader catalogue of SITC Cancer Immunotherapy Guidelines. These guidelines are developed by multi-disciplinary panels of experts who draw from their own practical experience and evidence in the published literature and clinical trial data, to develop evidence- and consensus-based recommendations on immunotherapy for patients with cancer. You can read the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal.
Instructions for Requesting Draft Manuscript
During SITC’s open comment period, key stakeholders and other experts in the field may critically review a confidential copy of the CPG draft and provide input prior to its publication. All participants must complete and sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by the noted deadline to be considered.
For more information on requesting the draft manuscript, please visit: sitcancer.org/CPGComment
DEADLINES:
- Non-disclosure and Confidentiality Agreement must be submitted to SITC by Thursday, Feb. 12, 2026.
- Comments on the draft manuscript must be submitted on or before Monday, Feb. 16, 2026 at 11:59 p.m. to be considered.